Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Research Grant, 2017
    Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)

    Objective/Rationale:
    The Michael J. Fox Foundation's Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson's disease (PD) and degenerative...

  • Therapeutic Pipeline Program, 2017
    Advancing Neuroprotective Protein Regulators Toward the Clinical Candidate Phase

    Study Rationale:
    Addex Pharmaceuticals has developed drug discovery tools that can be used to screen its small molecule compound library for positive allosteric modulators (protein regulators) of TrkB...

  • Therapeutic Pipeline Program, 2017
    Protein Homeostasis and the Ubiquitination Pathway in Parkinson's Disease

    Study Rationale:
    Parkinson's disease (PD) involves accumulation of toxic proteins in cells in specific areas of the brain. These cells normally have protective mechanisms to remove these toxic...

  • Research Grant, 2017
    Development of Analytic Tests to Use as Nilotinib Companion Diagnostics in Parkinson's Disease

    Study Rationale:
    Evidence suggests that increased activity of the c-abl protein in the brain may contribute to the development and progression of Parkinson's disease (PD). Nilotinib, a drug that...

  • Research Grant, 2017
    White Blood Cell and Urine Collection in LRRK2 and GBA Mutation Carriers

    Study Rationale:

    Mutations in the LRRK2 and GBA genes increase the risk for Parkinson's disease (PD). The mechanism by which these mutations increase PD risk is unknown. One potential explanation may...

  • Therapeutic Pipeline Program, 2017
    Small-Molecule Pharmacological Chaperones Reverse Alpha-synuclein-impaired Debris Removal

    Study Rationale:

    The goal of this project is to find therapeutic drugs for Parkinson's disease (PD) that target alpha-synuclein, a key player in PD. We propose that the negative impact of alpha...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.